You are here: Industry Insights > pomalidomide

News List

Yangtze River Receiving Another 2 Clinical Trial Implied Permissions CPhI.CN
April 27, 2020
Yangtze River Receiving Another 2 Clinical Trial Implied Permissions in the Battle for the First Generic of the Blockbuster MM Drug Pomalidomide.
FDA Approves Belumosudil for Graft-Versus-Host Disease americanpharmaceuticalreview
July 20, 2021
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including ...
NICE backs use of new treatment for multiple myeloma pharmatimes
November 27, 2020
Patients with a difficult to treat form of multiple myeloma will now gain access to a new treatment on the NHS in England and Wales, after cost regulators issued final guidance on the use of Sanofi's Sarclisa (isatuximab).
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study pharmatimes
August 04, 2020
Genmab and Janssen’s subcutaneous formulation of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone (Pd) has generated positive results in a phase 3 myeloma trial.
FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma americanpharmaceuticalreview
May 21, 2020
The Food and Drug Administration (FDA) expanded the indication of pomalidomide (POMALYST, Celgene Corporation).
US approves new use for BMS’ Empliciti pharmatimes
November 08, 2018
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received
Data show Imnovid-based triple therapy PFS benefit in blood cancer pharmatimes
July 05, 2018
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.